Robert C. Doebele

Also affiliated with University of Colorado Cancer Center, Aurora University, University of Colorado Denver

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 28 papers. Top paper: “Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study”.

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00247-3

N/A

5.0DataRank · unranked

445 citations

Giuseppe Curigliano, Dong‐Wan Kim, Ki Hyeong Lee, Benjamin Besse, Christina S. Baik +20 more

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study

Journal of Clinical Oncology(2024)10.1200/jco.24.00071

N/A

1.4DataRank · unranked

60 citations

Anatoly Urisman, Matthew A. Gubens, Claire K. Mulvey, Greg M. Allen, Stephen Shiboski +19 more

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3555

N/A

0.661DataRank · unranked

81 citations

Anh T. Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, Matthew R. Bull +6 more

Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway

npj Precision Oncology(2023)10.1038/s41698-023-00349-0

N/A

0.600DataRank · unranked

15 citations

Anh T. Le, Amanuail Gebregzabheir, Hala Nijmeh, Gregory B. Reis, Melanie Mandell +8 more

Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer

Journal of Thoracic and Cardiovascular Surgery(2022)10.1016/j.jtcvs.2022.10.007

N/A

0.568DataRank · unranked

43 citations

Alan Nicholas, G. Alexander Patterson, Salama N. Waqar, Eric M. Toloza, Eric B. Haura +24 more

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC

npj Precision Oncology(2021)10.1038/s41698-021-00231-x

N/A

0.492DataRank · unranked

11 citations

Tejas Patil, Anh T. Le, Kurtis D. Davies, Peter Brzeskiewicz, Hala Nijmeh +5 more

Development of syngeneic murine cell lines for use in immunocompetent orthotopic lung cancer models

Cancer Cell International(2020)10.1186/s12935-020-01503-5

N/A

0.483DataRank · unranked

24 citations

Gregory Verzosa, Tim Cleaver, Darinee Tippimanchai, Lisa DePledge, Xiao‐Jing Wang +6 more

Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance

Nature Communications(2024)10.1038/s41467-024-53451-7

N/A

0.457DataRank · unranked

20 citations

L. E. Roth, Thomas R. Mumford, Juan Guan, Anh‐Tuan Le, Robert C. Doebele +6 more

Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.05.007

N/A

0.457DataRank · unranked

20 citations

Igor Odintsov, Vladimir Markov, Rebecca Caeser, Paweł Sobczuk, Sam E. Tischfield +14 more

Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0762

N/A

0.385DataRank · unranked

12 citations

Thomas E. Stinchcombe, Mrinal M. Gounder, Gregory M. Coté, Glenn J. Hanna, Bradley Sumrall +16 more

Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC

Lung Cancer(2022)10.1016/j.lungcan.2022.07.010

N/A

0.385DataRank · unranked

12 citations

Wei‐Yun Lai, Anh T. Le, Jonatan L. Gabre, T-P. Chuang, Susanne Fransson +10 more

MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-23-0218

N/A

0.373DataRank · unranked

11 citations

Logan C. Tyler, Anh T. Le, Eric A. Welsh, Bin Fang, Andrew Elliott +7 more

Novel Human-Derived RET Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling

Molecular Pharmacology(2021)10.1124/molpharm.120.000207

N/A

0.360DataRank · unranked

10 citations

Anh T. Le, Adriana Estrada‐Bernal, Andrea E. Doak, Minjae Yoo, Sarah E. Ferrara +6 more

Targeting ALK, ROS1, and BRAF Kinases

Journal of Thoracic Oncology(2012)10.1097/jto.0b013e31826df05e

N/A

0.360DataRank · unranked

10 citations

D. Ross Camidge, Robert C. Doebele

Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2

Cell chemical biology(2023)10.1016/j.chembiol.2023.09.011

N/A

0.312DataRank · unranked

7 citations

Lily L. Remsing Rix, Xueli Li, Bin Fang, Victoria Izumi, Eric A. Welsh +6 more

Differential Chemoproteomics Reveals MARK2/3 as Cell Migration‐Relevant Targets of the ALK Inhibitor Brigatinib

ChemBioChem(2023)10.1002/cbic.202200766

N/A

0.292DataRank · unranked

6 citations

Yi Liao, J. Cao, Bin Fang, Sang Y. Yun, Fumi Kinose +6 more

A functional sgRNA-CRISPR screening method for generating murine RET and NTRK1 rearranged oncogenes

Biology Open(2023)10.1242/bio.059994

N/A

0.269DataRank · unranked

5 citations

Anh‐Tuan Le, Trista K. Hinz, Andre Navarro, Sarah K. Nelson-Taylor, Raphael A. Nemenoff +3 more

Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer

Frontiers in Oncology(2020)10.3389/fonc.2020.00510

N/A

0.208DataRank · unranked

3 citations

Jose M. Pacheco, Anastasios Dimou, W. Thomas Purcell, Candice Rossi, Paul A. Bunn +4 more

540P Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy

Annals of Oncology(2020)10.1016/j.annonc.2020.08.654

N/A

0.104DataRank · unranked

1 citations

Filippo de Braud, Alexander Drilon, Robert C. Doebele, Manish R. Patel, Byoung Chul Cho +15 more

A Rapid, Functional sgRNA Screening Method for Generating Murine RET and NTRK1 Fusion Oncogenes

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.04.06.535912

N/A

0DataRank · unranked

0 citations

Anh‐Tuan Le, Trista K. Hinz, Andre Navarro, Sarah K. Nelson-Taylor, Raphael A. Nemenoff +3 more

HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.08.023

N/A

0DataRank · unranked

13 citations

Paul Grewe, John Sidney, Alessandro Sette, Paul J. Norman, Robert C. Doebele +1 more

Duration of Targeted Therapy in Patients With Advanced Non–small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.06.015

N/A

0DataRank · unranked

13 citations

Tejas Patil, Kedar Kirtane, Thereasa A. Rich, Carin R. Espenschied, Caroline Weipert +5 more

Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000441

N/A

0DataRank · unranked

52 citations

Abigail K. Kimball, Amber M. Johnson, Benjamin W Arnold, Bonnie Bullock, Rachael E. Kaspar +9 more

Characterization of the tumor microenvironment landscape and deep learning-guided prediction of prognosis in lung adenocarcinoma with bulk RNA sequencing data.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e21025

N/A

0DataRank · unranked

0 citations

Wei Wu, Elizabeth A. Yu, Caroline E. McCoach, Robert C. Doebele, Trever G. Bivona +1 more

Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression

Thoracic Cancer(2023)10.1111/1759-7714.15116

N/A

0DataRank · unranked

2 citations

Nan Chen, Logan C. Tyler, Anh T. Le, Anastasios Dimou, Robert C. Doebele +1 more

Supplementary Figure S3 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

(2023)10.1158/1078-0432.22478576

N/A

0DataRank · unranked

0 citations

Anh T. Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, Matthew R. Bull +6 more

Data from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

(2023)10.1158/1078-0432.c.6529985

N/A

0DataRank · unranked

0 citations

Anh T. Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, Matthew R. Bull +6 more

Data from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

(2023)10.1158/1078-0432.c.6529985.v1

N/A

0DataRank · unranked

0 citations

Anh T. Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, Matthew R. Bull +6 more